ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

ABEO vs BCYC // OPERATING MARGIN

Abeona Therapeutics Inc. (NASDAQ) VS. Bicycle Therapeutics plc (NASDAQ) • 15-METRIC TALLY: ABEO 1 — BCYC 2
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ABEO VS. BCYC) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC ABEO BCYC SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin 73.70% — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -35.00% 0.00 TIE /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield — — — TIE /fcf-yield <GO>
Operating Margin ACTIVE -60.00% -60.00% 0.00 TIE /operating-margins <GO>
Net Profit Margin -60.00% -60.00% 0.00 TIE /net-margins <GO>
Revenue Growth (YoY) — 105.80% — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 0.20 0.20 0.00 TIE /balance-sheet <GO>
Piotroski F-Score Quality 3/9 2/9 +1.00 ABEO /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 36.1 48.1 -12.00 BCYC /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $260.8M $267.4M -$6.6M BCYC /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR ABEO REV BCYC REV ABEO GROSS % BCYC GROSS % ABEO FCF BCYC FCF
FY 2025 $5.8M $72.6M 73.7% — -$84.3M -$252.0M
FY 2024 $0 $35.3M — — -$58.5M -$166.0M
FY 2023 $3.5M $27.0M — — -$37.0M -$60.6M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ABEO // BETA —
BCYC // BETA —